13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
80 檔
20.4%
During the Q4 2025 filing period, Blue Owl Capital Holdings LP (CIK: 0001858703) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $664.5M across 80 reported positions.
Blue Owl Capital Holdings LP executed strategic sector rebalancing during Q4 2025, establishing 11 new positions while fully exiting 7 holdings and trimming 13 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Engene Holdings Inc | Stock-Other | 9.37% | -8.08% | EXIT | |
| 2 | NCDL | Nuveen Churchill Direct Lend | Stock-Other | 8.82% | -3.32% | -30.66% | |
| 3 | OBDC | Blue Owl Capital CORP | Stock-Financials | 8.06% | -2.73% | — | |
| 4 | LRMR | Larimar Therapeutics Inc | Stock-Other | 8.02% | -4.40% | +16.58% | |
| 5 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 7.51% | -3.07% | -6.37% | |
| 6 | CMPX | Compass Therapeutics Inc | Stock-Other | 5.74% | -2.99% | +33.76% | |
| 7 | HLLY | Holley Inc | Stock-Other | 5.29% | -1.81% | -14.72% | |
| 8 | CNTX | Context Therapeutics Inc | Stock-Other | 3.37% | -3.34% | +0.34% | |
| 9 | CNDT | Conduent Inc | Stock-Other | 2.86% | -0.62% | +8.20% | |
| 10 | RPTX | Repare Therapeutics Inc | Stock-Other | 2.76% | — | — | |
| 11 | CVEO | Civeo CORP | Stock-Other | 2.62% | -1.28% | EXIT | |
| 12 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 2.27% | +1.00% | -6.36% | |
| 13 | EYPT | Eyepoint Inc | Stock-Other | 2.21% | -1.52% | +6.80% | |
| 14 | PCOR | Procore Technologies Inc | Stock-Tech | 2.12% | — | — | |
| 15 | DELL | Dell Technologies -c | Stock-Tech | 2.09% | +1.53% | +2.89% | |
| 16 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.79% | -1.16% | EXIT | |
| 17 | MPLT | Maplight Therapeutics Inc | Stock-Other | 1.77% | -1.55% | — | |
| 18 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.76% | — | -73.36% | |
| 19 | IMA | Imagenebio Inc | Stock-Other | 1.75% | -0.48% | +52.29% | |
| 20 | IMMX | Immix Biopharma Inc | Stock-Other | 1.59% | -0.66% | — | |
| 21 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.51% | -0.78% | -49.66% | |
| 22 | IMRX | Immuneering CORP - Class A | Stock-Other | 1.35% | — | +20.91% | |
| 23 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.30% | -0.22% | -57.74% | |
| 24 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.30% | +0.14% | — | |
| 25 | PAYO | Payoneer Global Inc | Stock-Other | 1.23% | — | — | |
| 26 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.12% | -1.01% | EXIT | |
| 27 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.08% | — | -17.70% | |
| 28 | AQST | Aquestive Therapeutics Inc | Stock-Other | 1.05% | -0.91% | -58.00% | |
| 29 | CMPS | Compass Pathways PLC | Stock-Other | 1.00% | +0.96% | NEW | |
| 30 | ✓ | Adc Therapeutics SA | Stock-Other | 0.91% | -0.58% | — | |
| 31 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.90% | -0.84% | +96.95% | |
| 32 | NU | Nu Holdings Ltd. | Stock-Financials | 0.90% | — | — | |
| 33 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.74% | -0.60% | — | |
| 34 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.74% | — | -34.67% | |
| 35 | NIOBW | Niocorp Developments LTD -28 | Stock-Other | 0.51% | -0.08% | +60.34% | |
| 36 | JANX | Janux Therapeutics Inc | Stock-Other | 0.43% | — | — | |
| 37 | CHYM | Chime Financial Inc-cl A | Stock-Other | 0.31% | +0.28% | NEW | |
| 38 | EPD | Enterprise Products Partners | Stock-Energy | 0.31% | -0.32% | EXIT | |
| 39 | FLD | Fold Holdings Inc | Stock-Other | 0.30% | -0.24% | — | |
| 40 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.25% | -0.07% | — | |
| 41 | ✓ | Alpha Tau Medical LTD | Stock-Other | 0.12% | — | — | |
| 42 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.11% | -0.10% | EXIT | |
| 43 | ✓ | Stock-Other | 0.08% | -0.03% | EXIT | ||
| 44 | OMDA | Omada Health Inc | Stock-Other | 0.07% | — | — | |
| 45 | TTAN | Servicetitan Inc-a | Stock-Tech | 0.07% | — | -54.26% | |
| 46 | ✓ | Rezolve Ai LTD | Stock-Other | 0.07% | -0.02% | -1.24% | |
| 47 | 62C | Piper Sandler Cos | Stock-Other | 0.06% | — | — | |
| 48 | OPTXW | Omnilit Acquisition Cl A -23 | Stock-Other | 0.06% | -0.23% | EXIT | |
| 49 | ✓ | Alpha Modus Hldgs Inc | Stock-Other | 0.06% | -0.04% | EXIT | |
| 50 | BNAIW | Brand Engagement Netwo -cw27 | Stock-Other | 0.03% | -0.08% | +63.56% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CMPX | Compass Therapeutics Inc | +2.9% | +33.76% | Add |
| 2 | CGEM | Cullinan Therapeutics Inc | +2.9% | -6.37% | Trim |
| 3 | ✓ | Engene Holdings Inc | +2.4% | +2.53% | Add |
| 4 | LRMR | Larimar Therapeutics Inc | +2.2% | +16.58% | Add |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | +1.3% | +188.00% | Add |
| 6 | CNTX | Context Therapeutics Inc | +1.1% | +0.34% | Add |
| 7 | RPTX | Repare Therapeutics Inc | +0.9% | — | Unchanged |
| 8 | EYPT | Eyepoint Inc | +0.6% | +6.80% | Add |
| 9 | HLLY | Holley Inc | +0.6% | -14.72% | Trim |
| 10 | IMA | Imagenebio Inc | +0.4% | +52.29% | Add |
| 11 | CVEO | Civeo CORP | +0.4% | +16.74% | Add |
| 12 | NIOBW | Niocorp Developments LTD -28 | +0.2% | +60.34% | Add |
| 13 | IMRX | Immuneering CORP - Class A | +0.2% | +20.91% | Add |
| 14 | ELDN | Eledon Pharmaceuticals Inc | +0.1% | +96.95% | Add |
| 15 | MRKR | Marker Therapeutics Inc | +0.1% | — | Unchanged |
| 16 | ✓ | Alpha Modus Hldgs Inc | -0.1% | — | Unchanged |
| 17 | ✓ | Rezolve Ai LTD | -0.1% | -1.24% | Trim |
| 18 | CMPS | Compass Pathways PLC | -0.1% | -22.32% | Trim |
| 19 | TTAN | Servicetitan Inc-a | -0.1% | -54.26% | Trim |
| 20 | SHFS | Shf Holdings Inc | -0.2% | — | Unchanged |
| 21 | FLD | Fold Holdings Inc | -0.2% | — | Unchanged |
| 22 | 260 | Centessa Pharmaceuticals-adr | -0.2% | -17.70% | Trim |
| 23 | DELL | Dell Technologies -c | -0.2% | +2.89% | Add |
| 24 | PLRX | Pliant Therapeutics Inc | -0.2% | — | Unchanged |
| 25 | MLYS | Mineralys Therapeutics Inc | -0.5% | -34.67% | Trim |
| 26 | PVLA | Palvella Therapeutics Inc | -0.6% | -57.74% | Trim |
| 27 | SGMT | Sagimet Biosciences Inc-a | -0.6% | -6.36% | Trim |
| 28 | CNDT | Conduent Inc | -1% | +8.20% | Add |
| 29 | AQST | Aquestive Therapeutics Inc | -1.1% | -58.00% | Trim |
| 30 | RARE | Ultragenyx Pharmaceutical In | -2.4% | -49.66% | Trim |
| 31 | ROIV | Roivant Sciences Ltd. | -2.9% | -73.36% | Trim |
| 32 | NCDL | Nuveen Churchill Direct Lend | -4.4% | -30.66% | Trim |
| 33 | EVCM | Evercommerce Inc | — | EXIT | Sold out |
| 34 | PCOR | Procore Technologies Inc | — | NEW | New buy |
| 35 | IRON | Disc Medicine Inc | — | EXIT | Sold out |
| 36 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 37 | IMMX | Immix Biopharma Inc | — | NEW | New buy |
| 38 | KRRO | Korro Bio Inc | — | EXIT | Sold out |
| 39 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 40 | PAYO | Payoneer Global Inc | — | NEW | New buy |
| 41 | MREO | Mereo Biopharma Group Pl-adr | — | EXIT | Sold out |
| 42 | LENZ | Lenz Therapeutics Inc | — | NEW | New buy |
| 43 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 44 | JANX | Janux Therapeutics Inc | — | NEW | New buy |
| 45 | CHYM | Chime Financial Inc-cl A | — | NEW | New buy |
| 46 | TNGX | Tango Therapeutics Inc | — | EXIT | Sold out |
| 47 | GTLB | Gitlab Inc-cl A | — | EXIT | Sold out |
| 48 | ✓ | Alpha Tau Medical LTD | — | NEW | New buy |
| 49 | ✓ | — | NEW | New buy | |
| 50 | OMDA | Omada Health Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 80 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ENGENE HOLDINGS INC, NCDL, OBDC) accounted for 20.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
PCOR
市值: $6.9M
Top Position Liquidated / Trimmed
EVCM
前期市值: $18.3M
During Q4 2025, Blue Owl Capital Holdings LP's top holdings by market value included ENGENE HOLDINGS INC (9.4%)、NCDL (8.8%)、OBDC (8.1%). The largest single position, ENGENE HOLDINGS INC, represented 9.4% of total portfolio value.
In Q4 2025, Blue Owl Capital Holdings LP made 44 total portfolio adjustments, initiating 11 new buys, adding to 13 positions, trimming 13 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.